Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Type 2 Diabetes Diagnosis

Insulin Resistance Diagnosis

What is Diabetes?

Type 2 Diabetes Treatment

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Living With Type 2 Diabetes

Insulin Resistance Treatment

Insulin Resistance and Parkinson's Disease

The Risks of Prediabetes

Diabetes Mellitus Type 2 Pathophysiology

Causes of Insulin Resistance

See more featured articles »

Diabetes in Men versus Women

Vitamin D and Type 2 Diabetes

Insulin Resistance Pathophysiology

Type 2 Diabetes Symptoms

Does the Keto Diet Increase the Risk of Diabetes?

Type 2 Diabetes Screening and Prevention

Fibromyalgia and Diabetes

Insulin Medication

Is a Plant-Based Diet Good for Type 2 Diabetes?

Insulin Resistance Symptoms

What is Insulin Resistance?

Latest Type 2 Diabetes News and Research

U.S. bariatric surgery rates drop significantly amid GLP-1 surge

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery improves outcomes for patients with obesity and chronic kidney disease

Metabolic and bariatric surgery, also known as weight-loss surgery, dramatically improves outcomes for patients with obesity and chronic kidney disease (CKD), significantly reducing the risk of kidney failure, major cardiovascular events and death, according to new research presented here today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

GLP-1 use surges as surgery rates drop for severe obesity

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially -- from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 -- according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery costs significantly less than GLP-1 drugs over two years

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to a new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Study links antimicrobial peptides to amyloid disease and neurodegeneration

For decades, antimicrobial peptides (AMPs) and amyloid-forming peptides were studied in largely separate contexts.

5 May 2026

Study reveals epigenetic adaptation of beta cells across lifespan and disease

As people age, most maintain normal blood sugar even as insulin resistance tends to rise. New research suggests that pancreatic beta cells help meet this demand through gradual epigenetic changes in regulatory regions of the genome that support beta-cell identity and function.

5 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

A new tool that predicts obesity-related disease risk beyond BMI

OBSCORE is a data-driven tool that identifies high-risk individuals for obesity-related diseases, enhancing treatment targeting beyond traditional BMI metrics.

5 May 2026

Virginia Tech researcher wins NIH award to study metabolic brain health

Mary Elizabeth Baugh, a research scientist with Virginia Tech's Fralin Biomedical Research Institute at VTC, has been awarded a National Institutes of Health Mentored Research Scientist Development Award to study how metabolic health influences the brain systems that shape what and how we eat.

4 May 2026

A more accurate tool for assessing Arsenic toxicity

Public health experts estimate that more than 200 million people worldwide are exposed to arsenic through contaminated drinking water. Scientists know long-term exposure to arsenic is associated with increased risk of chronic illnesses like cancer and cardiovascular disease, but there hasn't been a reliable way to track these exposures and fully understand their effects on the body and the mechanisms behind them.

4 May 2026

Child health experts launch GenHEART to tackle Australia's obesity crisis

Heart health, diet, exercise and sleep will be targeted under a multi-pronged strategy by child health experts to address Australia's obesity crisis.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

New genetic risk report reveals hidden heart disease risk before symptoms appear

Researchers developed and externally validated integrated polygenic risk scores for eight cardiovascular conditions using large U.S.-based biobank data. The clinically orderable report may help identify inherited cardiovascular risk that traditional clinical markers can miss, although broader prospective validation is still needed.

30 Apr 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

Meth use accounts for nearly 1 in 6 heart attacks, California study shows

Methamphetamine (meth) use accounted for nearly 15% of heart attacks for a decade in a northern California study, published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

30 Apr 2026

New screening tool predicts health risks for people living with obesity

A simple tool, developed by researchers at Queen Mary University of London and the Berlin Institute of Health at Charité, could help identify which people living with obesity or overweight are most likely to develop serious obesity-related conditions such as type 2 diabetes and heart disease.

30 Apr 2026

Brief walking breaks help the body control sugar after carb-rich meals

Brief brisk walking breaks during prolonged sitting improved post-meal interstitial glucose responses in healthy adults after carbohydrate-rich meals, with the strongest effects seen in women. Gluteal fat showed a more stable glucose pattern than abdominal fat, suggesting it may help buffer carbohydrate-related glucose rises through depot-specific uptake and lipid-synthesis pathways.

29 Apr 2026

New genetic risk test estimates inherited risk for cardiovascular conditions

Researchers at Mass General Brigham Heart and Vascular Institute and collaborators have developed and validated a new genetic risk test that can estimate a person's inherited risk for eight common cardiovascular conditions, offering a more comprehensive approach to prevention.

29 Apr 2026

New hybrid molecule uses Trojan horse approach to treat obesity

A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity and type 2 diabetes: a hybrid molecule uses the well-known GLP-1/GIP signalling pathway as a "door opener" and delivers an additional metabolic modulator specifically into the target cells.

29 Apr 2026

AI eye screening shows promise for detecting six metabolic diseases

Researchers developed Reti-Pioneer, an AI retinal imaging framework that screened for six endocrine and metabolic diseases using color fundus photographs and clinical metadata. The system showed moderate-to-strong performance across cohorts, improved specialist decision-making, and demonstrated promising, though still preliminary, potential for faster, scalable disease screening.

29 Apr 2026